News

A certain blood protein regarded as an early indicator of Alzheimer's disease also appears to play a role in other disorders. Researchers at DZNE and the Hertie…

“It took almost three years to get a proper diagnosis,” said Scott, a retired firefighter and paramedic who has hereditary transthyretin amyloidosis (hATTR). It is…

ATTRACTnet was developed as an AI-based screening tool for transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). In a real-world population, use of the…

Hereditary transthyretin‐mediated amyloidosis (hATTR) is a disorder that affects several body systems and can result in life‐threatening conditions like…

The US Food and Drug Administration (FDA) has released the clinical hold on a second trial evaluating Intellia Therapeutics’ transthyretin amyloidosis with…

CAMBRIDGE, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing…

Cardiomyopathy associated with wild-type or hereditary transthyretin amyloidosis (ATTR-CM) is a serious, progressive, and ultimately fatal disease.3,4 There is…

Despite advances in noninvasive diagnostic techniques, patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) in the Czech Republic still experience…

For many people living with amyloidosis, the journey to diagnosis can be long and overwhelming. Symptoms can be vague, overlap with other conditions and affect…

Jimmy Addison had just moved from Atlanta to Seneca, South Carolina, when he noticed something wasn’t right. “I started gaining weight and didn't know what was…